WD repeat and SOCS box containing 2Genealiases: LAGNS · SBA2
Q-omics provides the consensus-scored WSB2 profile across patient tissues and cancer cell-line models. WSB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, WSB2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, WSB2 RNA expression shows 19,931 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, BLCA, and ACC as cancer lineages where WSB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WSB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WSB2 survival associations across molecular data types. WSB2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WSB2 RNA expression–survival associations across cancer types. High WSB2 expression shows unfavorable associations in MESO, LIHC, KICH, CESC, ACC and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for WSB2 RNA expression.
This table summarizes WSB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WSB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WSB2 shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, KIRC, KIRP and UCEC. The BLCA box plot shows higher WSB2 RNA expression in tumor versus normal tissue (log2 FC = +0.520, t-test p = .002).
This table shows molecular features associated with WSB2 in patient tissues and cancer cell lines. In patient samples, WSB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WSB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
